CTOs on the Move

GI Alliance

www.gialliance.com

 
At the core, GI Alliance operates on a philosophy grounded by three guiding principles: Patient First. Quality Centric. Provider-Led. Our strength comes from the diversity of talented individuals who make up our organization—everyone striving to serve our patients with excellence every day. We have designed our practice to foster and develop a diverse culture, both clinical and non-clinical. It is not merely words for our practice. Our company values and celebrates the diversity of our physicians, staff and patients. We firmly believe our service is greatly enriched by our diversity of thought, experience, perspective, culture and background. The people of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Fred Clayton
Director Information and Cyber Security Profile

Funding

GI Alliance raised $25.2M on 03/18/2021

Similar Companies

Christ Community Health Services Augusta

Christ Community Health Services Augusta is a non-profit organization that provides affordable, quality primary health and dental care for the uninsured, the under insured and the under served of Augusta, Georgia.

River Edge Behavioral Health Center

River Edge Behavioral Health Center has been providing mental health, mental retardation and substance abuse services to the citizens of Middle Georgia since 1994. River Edge strives to be the leader in behavioral healthcare providing comprehensive

St. John's Hospital

St. John's Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. St. John's Hospital is based in Springfield, IL. You can find more information on St. John's Hospital at www.st-johns.org

Healthcare Commons Inc

Healthcare Commons Inc is a Penns Grove, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.